TW432073B - Pyrazolopyridine compounds - Google Patents

Pyrazolopyridine compounds Download PDF

Info

Publication number: TW432073B
Authority: TW; Taiwan
Prior art keywords: light; growth hormone; compounds; temperature; useful
Prior art date: 1995-12-28

Application number

TW085113857A

Other languages

English (en)

Inventor

Philip A Carpino

Paul A Dasilva Jardine

Bruce A Lefker

John A Ragan

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-28

Filing date

1996-11-13

Publication date

2001-05-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21737850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW432073(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-11-13 Application filed by Pfizer filed Critical Pfizer

2001-05-01 Application granted granted Critical

2001-05-01 Publication of TW432073B publication Critical patent/TW432073B/zh

Links

150000005229 pyrazolopyridines Chemical class 0.000 title 1
238000011084 recovery Methods 0.000 abstract description 2
230000004044 response Effects 0.000 abstract description 2
150000001875 compounds Chemical class 0.000 abstract 5
102000018997 Growth Hormone Human genes 0.000 abstract 3
108010051696 Growth Hormone Proteins 0.000 abstract 3
239000000122 growth hormone Substances 0.000 abstract 3
102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 abstract 2
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 abstract 2
208000001132 Osteoporosis Diseases 0.000 abstract 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
101710142969 Somatoliberin Proteins 0.000 abstract 2
229940011871 estrogen Drugs 0.000 abstract 2
239000000262 estrogen Substances 0.000 abstract 2
230000013632 homeostatic process Effects 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 abstract 1
NWQWNCILOXTTHF-HLCSKTDOSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CNC=N1 NWQWNCILOXTTHF-HLCSKTDOSA-N 0.000 abstract 1
WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 abstract 1
RVWNMGKSNGWLOL-GIIHNPQRSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 RVWNMGKSNGWLOL-GIIHNPQRSA-N 0.000 abstract 1
DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 abstract 1
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 abstract 1
102100033367 Appetite-regulating hormone Human genes 0.000 abstract 1
101710111255 Appetite-regulating hormone Proteins 0.000 abstract 1
229940122361 Bisphosphonate Drugs 0.000 abstract 1
208000010392 Bone Fractures Diseases 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
102000055006 Calcitonin Human genes 0.000 abstract 1
108060001064 Calcitonin Proteins 0.000 abstract 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
208000017667 Chronic Disease Diseases 0.000 abstract 1
208000036119 Frailty Diseases 0.000 abstract 1
206010019280 Heart failures Diseases 0.000 abstract 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
230000032683 aging Effects 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
108010083553 alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide Proteins 0.000 abstract 1
229940062527 alendronate Drugs 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
206010003549 asthenia Diseases 0.000 abstract 1
-1 bisphosphonate compound Chemical class 0.000 abstract 1
229960004015 calcitonin Drugs 0.000 abstract 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 1
230000001925 catabolic effect Effects 0.000 abstract 1
JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 abstract 1
108010015153 growth hormone releasing hexapeptide Proteins 0.000 abstract 1
239000003324 growth hormone secretagogue Substances 0.000 abstract 1
108010070965 hexarelin Proteins 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000012423 maintenance Methods 0.000 abstract 1
230000002503 metabolic effect Effects 0.000 abstract 1
210000003205 muscle Anatomy 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
229940063238 premarin Drugs 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
239000000186 progesterone Substances 0.000 abstract 1
229960003387 progesterone Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 abstract 1
230000029663 wound healing Effects 0.000 abstract 1
238000001816 cooling Methods 0.000 description 16
238000001514 detection method Methods 0.000 description 15
238000013021 overheating Methods 0.000 description 11
230000017525 heat dissipation Effects 0.000 description 3
230000005611 electricity Effects 0.000 description 2
238000000034 method Methods 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 1
238000009529 body temperature measurement Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000835 fiber Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Crystallography & Structural Chemistry (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Neurology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Cooling Or The Like Of Electrical Apparatus (AREA)
Steroid Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

M432073 作，使得嵌入式控制器必須依據反饋回來的溫度偵測結果而對應輸出脈波寬度調變訊號。另一方面，這種超溫保護方式通常還會搭配多個溫度的預設臨界值來進行分段控制，使得嵌入式控制器必須依照不同的溫度區段對應輸出脈波寬度調變訊號。因此，這種超溫保護方式的反應就顯得不夠迅速靈敏。台灣1353494號專利案提供的散熱風扇控制電路則在於解決前述習知嵌入式控制器的問題，其可依照環境溫度而決定是否切 φ 換成以手動方式來調整脈波寬度調變訊號的脈波寬度，進而以調整後的脈波寬度調變訊號去控制散熱風扇的轉速。然而，以手動方式來調整脈波寬度不僅無法靈活反應溫度的變化’且使用上也較不方便。【新型内容】本創作的目的，在於解決習知散熱風扇僅具有單純排熱功能 φ而無過熱警示功能；而台灣η53·號專利案提供的可切換成以手動方式來調整脈波寬度以控制散熱風扇的轉速，不僅無法靈活反應溫度的變化，且使用上也較不方便的問題。本創作的舰，是錢扇本體設有至少—發光單元與一溫度偵測電路’該溫度偵測電路電性連接所述發光單元，當溫度制電路债測到溫度升高至—特定辦，該溫度_電路驅使該發光單元發光’所述發光單找至可以發出不嶋色的光來提供使用者韻散熱風扇是在正常使用狀態，或過熱狀態的示警。 4 本創作的撕手段，包括有-風扇描、至少—發光單元與 —溫度侧電路；所述發光單元與溫度_!電路触於該風扇本體’且溫度侧電路紐連接所述發光單元，#該溫度侧到電路的溫度升高至-特定值時，該溫度偵測電路即驅使該發光單元發光。賴作的發林it可以包含分別發出不_色的—第一光源、第-光源戶/f述溫度伽彳電路則包括有―熱敏電阻…連通 "亥第光源的第一電晶體，以及一連通該第二光源的第二電晶體，當電路在常溫狀_，所述第—電晶體未導通而使該第一光源不發光’但第二電晶體導通而使該第二光源發光；當電路的溫度升高時，則藉由該熱敏電阻的電阻值降低而使該第—電晶體導通致使該第一光源發I但第二電晶體則不導通致使該第二光源不發光。基於使用壽命長與省電的考量，所述光源是使用發光二極體 (LED) ° 為了使散熱風扇的多個方位均能看到光源的狀態，本創作可以在風扇本體設置複數組發光單元。為了讓使用者可以清楚地分辨散熱風扇是在常溫的運轉狀態或過熱的運轉㈣’本創作可以制能發出紅光的㈣做為所述第一光源，以及制能發峰光的LED做為所述第二光源。本創作的温度侧魏可叫麵縣體共同使—電源，藉此，當散賊祕纽_無法排出熱能，紐應散熱風扇的電該溫度偵測電路可以㈣作動讓光源流發生異常而升高溫度時，發光警示。本創作具有過歸示裝置的散熱_，除了可機殼提供勒勃^田冰,_ 電腦器、主機板恢：供放熱之用外’也可以應用在電源供應卡等單獨需要散熱的裝置或設備。【實施方式】以下配合®式及it件符號對本創_實施方式做更詳如明，俾使翻_聽者在研讀本酬書後能據以實施。的說與第二圖所示，本創作提供的具有過熱警示政熱風扇，其較佳實施例包括有：-風扇本體卜複數發光早心與-溫度_電路3 ;其中，風扇本體i包含有—框體1〇以及設於該框體中央由馬糊中未顯示）驅動旋轉的扇葉⑴框 —的中央位置可以安裝所述溫度侧電路3，該溫度偵測電路 3可以直接於框體1G的中央，也可以將溫度制電路3設於-電路板30後’再將電路板30設於框體10 ;從框體10的中央往框體周邊U複數具有凹槽121的肋條a，框體⑺的周絲設複數發光單元2 ’各發光單元2與溫度價測電路3之間以電源線4 电性連接’且電源線4被妥善地置人凹槽121内。走在本創麵較佳實施例，所述發光單元2是由—可發出紅光的第光源21 ’以及—可發出藍光的第二光源22組構而成，基於使用可v長且$、電的考量’本齡是制發光二極體()做為所 M432073 下所作有關本創作之任何修飾或變更，皆仍應包括在本創作意圖 . 保護之範轉。 M432073 【圖式簡單說明】第一圖為顯示本創作散熱風扇外觀之實施例立體圖。第二圖為顯示本創作在風扇本體設置複數光源與溫度偵測電路之貫施例平面不意圖。第三圖為顯示本創作之溫度偵測電路圖。【主要元件符號說明】

1···· ••風扇本體 10… …框體 11··· …扇葉 12··· …肋條 121. .....凹槽 2…·. ••發光單元 21··· …弟光源 22… …第二光源 3… •溫度偵測電路 30··· …電路板 31··· …驅動電路 32A.· •…第一電阻 32B.· •…第二電阻 33A·· •…第一電晶體 33B- …·第二電晶體電源線

1V1H-JZU / J 1V1H-JZU / J J：h- -rj> c本^利說明書押負序 1 铁 - L 一 __ ※申請案號：i—勿任意更動’※記號部分請勿填 ※申請日：脱1.2Λ , . r \{ -、新型名稱：（中4文广pc分類：6… *有過熱警示敦置的散熱風扇二、中文新型摘要： —種具有過婦轉置的散熱風扇，係麵扇本體設有至少 • -，光單it與-溫度偵測電路，該溫度偵測電路電性連接所述ς 光單元，當溫度侧電路侧到溫度升高至—特定值時該溫度偵測電路驅使該發光單元發光，所述發光單元甚至可以發出不同顏色的光來^供使用者散熱風扇是在正常使用狀態，或過熱狀雜的示警·。 _三、英文新型摘要：六、申請專利範圍： 1. 一種具有過熱警示裝置的散熱風扇，包括有：一風扇本體；至少一發光單元，設於該風扇本體；溫度侧《，設祕朗讀，物域接輯發光單元，當該溫度伽i電路偵泰丨溫度升高至―特定辦，該溫度债測電路驅使該發光單元發光。又、 2. 依據申請專纖圍第丨項所述之具有過㈣示裝置的散敎風扇，其中，該發光單元包含有分财發出不_色的一第一光源與-第二光源，所述溫度摘測電路包括有一熱敏電阻、 -連通该第-光源的第-電晶體，以及-連通該第二光源的第二電晶體’當電路在常溫狀態時’所述第—電晶體未導通而使該第-統*秋’但第二電晶體導咖使該第二光源發光’當.電路的溫度升局時，則藉由該熱敏電阻的電阻值降低而使該第一電晶體導通致使該第一光源發光，但第二電晶體則不導通致使該第二光源不發光。 3. 依據申請專利範圍第2項所述之具有過熱警示裝置的散熱風扇’其中，該第一光源與第二光源為led。 4. 依據申請專利範圍第2項所述之具有過熱警示裝置的散熱風扇，其申，s亥弟一光源為可發出紅光的led，該第二光源為可發出藍光的LED。 5. 依據申請專利範圍第4項所述之具有過熱警示裝置的散熱風 M432073 扇，其中，該發光單元包含有二組以上。 6. 依據申請專利範圍第1項所述之具有過熱警示裝置的散熱風扇，其中，該溫度偵測電路和該風扇本體共同連接一電源。 7. 依據申請專利範圍第1項所述之具有過熱警示裝置的散熱風扇，其中，所述溫度偵測電路設於一電路板上，該電路板則設於該風扇本體。

TW085113857A 1995-12-28 1996-11-13 Pyrazolopyridine compounds TW432073B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US946995P	1995-12-28	1995-12-28

Publications (1)

Publication Number	Publication Date
TW432073B true TW432073B (en)	2001-05-01

Family

ID=21737850

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW085113857A TW432073B (en)	1995-12-28	1996-11-13	Pyrazolopyridine compounds

Country Status (43)

Country	Link
US (7)	US6107306A (zh)
EP (1)	EP0869968B1 (zh)
JP (2)	JP3511382B2 (zh)
KR (1)	KR100320167B1 (zh)
CN (1)	CN1113895C (zh)
AP (2)	AP756A (zh)
AR (2)	AR004367A1 (zh)
AT (1)	ATE361314T1 (zh)
AU (1)	AU716934B2 (zh)
BG (1)	BG64055B1 (zh)
BR (1)	BR9612465B1 (zh)
CA (1)	CA2241725C (zh)
CO (1)	CO4480108A1 (zh)
CZ (1)	CZ293423B6 (zh)
DE (1)	DE69637063T2 (zh)
DK (1)	DK0869968T3 (zh)
EG (1)	EG24195A (zh)
ES (1)	ES2285715T3 (zh)
GT (1)	GT199600100A (zh)
HN (1)	HN1996000085A (zh)
HR (1)	HRP960618B1 (zh)
HU (1)	HUP9901246A3 (zh)
IL (4)	IL138911A (zh)
IS (1)	IS4758A (zh)
MA (1)	MA26415A1 (zh)
MX (1)	MX9805157A (zh)
MY (1)	MY135727A (zh)
NO (1)	NO325135B1 (zh)
NZ (1)	NZ322172A (zh)
OA (1)	OA10702A (zh)
PE (1)	PE30398A1 (zh)
PL (1)	PL186916B1 (zh)
PT (1)	PT869968E (zh)
RS (1)	RS49926B (zh)
SA (1)	SA97170581B1 (zh)
SI (1)	SI0869968T1 (zh)
SK (1)	SK285678B6 (zh)
TN (1)	TNSN96172A1 (zh)
TR (1)	TR199801233T2 (zh)
TW (1)	TW432073B (zh)
UA (1)	UA66754C2 (zh)
WO (1)	WO1997024369A1 (zh)
ZA (1)	ZA9610858B (zh)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW432073B (en) *	1995-12-28	2001-05-01	Pfizer	Pyrazolopyridine compounds
HN1996000101A (es)	1996-02-28	1997-06-26	Inc Pfizer	Terapia combinada para la osteoporosis
UA72439C2 (en)	1997-04-15	2005-03-15		Pharmaceutical compositions containing appetite suppressant agent
GB2324726A (en) *	1997-05-01	1998-11-04	Merck & Co Inc	Combination Therapy for the Treatment of Osteoporosis
USRE38524E1 (en)	1997-06-25	2004-06-01	Pfizer Inc.	Dipeptide derivatives as growth hormone secretagogues
UA64751C2 (uk) *	1997-06-25	2004-03-15	Пфайзер Продактс Інк.	Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) *	1997-06-25	2003-02-17	Пфайзер Продактс Інк.	Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
ZA987383B (en) *	1997-08-19	2000-02-17	Lilly Co Eli	Treatment of congestive heart failure with growth hormone secretagogues.
US6329342B1 (en)	1997-08-19	2001-12-11	Eli Lilly And Company	Treatment of congestive heart failure with growth hormone secretagogues
US6893877B2 (en)	1998-01-12	2005-05-17	Massachusetts Institute Of Technology	Methods for screening substances in a microwell array
CA2318558A1 (en)	1998-01-16	1999-07-22	Novo Nordisk A/S	Compounds with growth hormone releasing properties
US6657063B1 (en) *	1998-04-30	2003-12-02	Pfizer Inc.	Combinations of β3 agonists and growth hormone secretagogues
PL344699A1 (en) *	1998-06-03	2001-11-19	Pfizer Prod Inc	2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors
ID26726A (id) *	1998-06-16	2001-02-01	Pfizer Prod Inc	Kombinasi terapeutik untuk kelemahan muskuloskeletal
ZA993975B (en) *	1998-06-16	2000-12-15	Pfizer Prod Inc	Combination therapy for musculoskeletal frailty.
PA8471201A1 (es) *	1998-06-16	2000-09-29	Pfizer Prod Inc	Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
US6639076B1 (en)	1998-08-18	2003-10-28	Eli Lilly And Company	Growth hormone secretagogues
US6358951B1 (en)	1998-08-21	2002-03-19	Pfizer Inc.	Growth hormone secretagogues
CA2341649A1 (en) *	1998-09-02	2000-03-09	Merck & Co., Inc.	Enhancement of return to independent living status with a growth hormone secretagogue
PT1112095E (pt)	1998-09-11	2003-04-30	Axel Stemberger	Implantes biologicamente activos
US6337332B1 (en)	1998-09-17	2002-01-08	Pfizer Inc.	Neuropeptide Y receptor antagonists
US6380184B1 (en)	1998-10-28	2002-04-30	Bristol-Myers Squibb Co.	Benzoazepines and analogs thereof useful as growth hormone secretagogues
US6194578B1 (en) *	1998-11-20	2001-02-27	Pfizer Inc.	Dipeptide derivatives
SI1004583T1 (en) *	1998-11-23	2004-12-31	Pfizer Products Inc.	Process and hydantoin intermediates for the synthesis of growth hormone secretagogues
US6297380B1 (en)	1998-11-23	2001-10-02	Pfizer Inc.	Process and intermediates for growth hormone secretagogues
JP2002542151A (ja)	1999-02-18	2002-12-10	科研製薬株式会社	成長ホルモン分泌促進物質としての新規なアミド誘導体
US6828331B1 (en)	1999-02-19	2004-12-07	Eli Lilly And Company	Growth hormone secretagogues
US6541634B2 (en)	1999-02-26	2003-04-01	Pfizer Inc.	Process for preparing growth hormone secretagogues
US6525203B1 (en)	1999-03-12	2003-02-25	Bristol-Myers Squibb Company	Heterocyclic aromatic compounds useful as growth hormone secretagogues
US6518292B1 (en)	1999-03-12	2003-02-11	Bristol-Myers Squibb Co.	Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
KR20020047096A (ko)	1999-07-26	2002-06-21	크로커 사무엘 에스	초활성 돼지 성장 호르몬 분비 호르몬 유사체
GB2355657B (en)	1999-10-27	2004-07-28	Phytopharm Plc	Inhibitors Of Gastric Acid Secretion
EP1113007A1 (en) *	1999-12-24	2001-07-04	Pfizer Inc.	Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
EP1258250B1 (en) *	1999-12-28	2005-09-14	Kaken Pharmaceutical Co., Ltd.	Nerve protective drugs
WO2001061054A2 (en) *	2000-02-18	2001-08-23	Board Of Trustees Of The Leland Stanford Junior University	Apparatus and methods for parallel processing of micro-volume liquid reactions
US20020151040A1 (en)	2000-02-18	2002-10-17	Matthew O' Keefe	Apparatus and methods for parallel processing of microvolume liquid reactions
EP1132388A3 (en) *	2000-03-09	2004-03-03	Pfizer Products Inc.	Hexahydropyrazolo[4,3-c]pyridine metabolites
EP1149583A3 (en) *	2000-04-13	2001-11-14	Pfizer Products Inc.	Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
MXPA02010452A (es)	2000-05-11	2003-06-06	Bristol Myers Squibb Co	Analogos de tetrahidroisoquinolina utiles como secretagogos de la hormona del crecimiento.
DOP2001000154A (es) *	2000-05-25	2002-05-15	Pfizer Prod Inc	Combinación de secretagogos de hormona del crecimiento y antidepresivos
WO2001091752A1 (en)	2000-05-30	2001-12-06	Merck & Co., Inc.	Melanocortin receptor agonists
DE60140285D1 (de) *	2000-05-31	2009-12-10	Pfizer Prod Inc	Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
IL143690A0 (en) *	2000-06-19	2002-04-21	Pfizer Prod Inc	The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
IL143942A0 (en) *	2000-06-29	2002-04-21	Pfizer Prod Inc	Use of growth hormone secretagogues for treatment of physical performance decline
EP1181933A3 (en) *	2000-06-29	2002-04-10	Pfizer Products Inc.	Use of growth hormone secretagogues for stimulating or increasing appetite
GB2363985B (en)	2000-06-30	2004-09-29	Phytopharm Plc	Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
IL144468A0 (en) *	2000-07-27	2002-05-23	Pfizer Prod Inc	Use of growth hormone secretagogues for improvement of functional health status
MXPA03001771A (es)	2000-08-30	2003-06-04	Pfizer Prod Inc	Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
IL145106A0 (en) *	2000-08-30	2002-06-30	Pfizer Prod Inc	Intermittent administration of a geowth hormone secretagogue
IL145540A0 (en) *	2000-09-28	2002-06-30	Pfizer Prod Inc	Use of growth hormone secretagogues in conjunction with physical exercise
US20100261159A1 (en)	2000-10-10	2010-10-14	Robert Hess	Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
AU2001296809A1 (en) *	2000-10-10	2002-04-22	Biotrove, Inc.	Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
CA2372450A1 (en) *	2001-05-10	2001-09-19	Pharmaceutical Partners Of Canada Inc.	Liquid injectable formulation of disodium pamidronate
US7125840B2 (en)	2001-10-09	2006-10-24	Eli Lilly And Company	Substituted dipeptides as growth hormone secretagogues
US6649606B1 (en)	2001-11-09	2003-11-18	Bristol-Myers Squibb Co.	Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US20030199514A1 (en) *	2002-03-27	2003-10-23	Fryburg David A.	Methods for improving efficacy of treatment with growth hormone secretagogues
AU2003218337A1 (en) *	2002-04-09	2003-10-27	Eli Lilly And Company	Growth hormone secretagogues
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
US8277753B2 (en) *	2002-08-23	2012-10-02	Life Technologies Corporation	Microfluidic transfer pin
RU2005111253A (ru) *	2002-09-18	2005-11-20	Сантр Оспиталье Де Л` Юниверсите Де Монреаль (Схюм) (Ca)	Аналоги ghrh
EP1608952B1 (en) *	2002-12-20	2016-08-10	Life Technologies Corporation	Assay apparatus and method using microfluidic arrays
US20060094108A1 (en) *	2002-12-20	2006-05-04	Karl Yoder	Thermal cycler for microfluidic array assays
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
WO2004108120A1 (en) *	2003-06-11	2004-12-16	Pfizer Products Inc.	Use of growth hormone secretagogues for treatment of fibromyalgia
US7476653B2 (en)	2003-06-18	2009-01-13	Tranzyme Pharma, Inc.	Macrocyclic modulators of the ghrelin receptor
WO2005027913A1 (en) *	2003-09-19	2005-03-31	Pfizer Products Inc.	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
AU2004274309B2 (en)	2003-09-22	2010-04-08	Msd K.K.	Novel piperidine derivative
US7129561B2 (en) *	2003-11-19	2006-10-31	International Business Machines Corporation	Tri-metal and dual-metal stacked inductors
JP2007529015A (ja)	2004-03-12	2007-10-18	バイオトローブ，インコーポレイテッド	ナノリットルのアレイローディング
CA2561801A1 (en) *	2004-04-02	2005-10-20	Elixir Pharmaceuticals, Inc.	Sulfonamides and uses thereof
EP1734963A4 (en)	2004-04-02	2008-06-18	Merck & Co Inc	METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
WO2005097174A2 (en) *	2004-04-07	2005-10-20	Gastrotech Pharma A/S	Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
AU2005266448A1 (en)	2004-07-28	2006-02-02	Glaxo Group Limited	Piperazine derivatives useful for the treatment of gastrointestinal disorders
US20060105453A1 (en)	2004-09-09	2006-05-18	Brenan Colin J	Coating process for microfluidic sample arrays
US12070731B2 (en)	2004-08-04	2024-08-27	Life Technologies Corporation	Methods and systems for aligning dispensing arrays with microfluidic sample arrays
EP1789067B8 (en) *	2004-08-12	2012-08-15	Helsinn Healthcare S.A.	Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system
AU2005277389A1 (en)	2004-08-18	2006-03-02	Elixir Pharmaceuticals, Inc.	Growth-hormone secretagogues
CA2609388C (en)	2005-05-30	2013-08-06	Banyu Pharmaceutical Co., Ltd.	Novel piperidine derivative
WO2007018248A1 (ja)	2005-08-10	2007-02-15	Banyu Pharmaceutical Co., Ltd.	ピリドン化合物
EP1921065B1 (en)	2005-08-24	2010-10-20	Banyu Pharmaceutical Co., Ltd.	Phenylpyridone derivative
CA2621470A1 (en)	2005-09-07	2007-03-15	Banyu Pharmaceutical Co., Ltd.	Bicyclic aromatic substituted pyridone derivative
KR20080048502A (ko)	2005-09-29	2008-06-02	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
WO2007048027A2 (en)	2005-10-21	2007-04-26	Novartis Ag	Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
AU2006307046A1 (en)	2005-10-27	2007-05-03	Msd K.K.	Novel benzoxathiin derivative
US8158791B2 (en)	2005-11-10	2012-04-17	Msd K.K.	Aza-substituted spiro derivatives
CA2630006A1 (en) *	2005-11-21	2007-05-24	Asubio Pharma Co., Ltd.	Skin repair accelerating therapeutic agent containing ghrelin and derivatives thereof or substance acting on ghs-r1a as active ingredient
US8273702B2 (en) *	2006-02-17	2012-09-25	Wake Forest University Health Sciences	Wound healing compositions containing keratin biomaterials
CU23592A1 (es) *	2006-02-28	2010-11-11	Ct Ingenieria Genetica Biotech	Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6
CU23558A1 (es)	2006-02-28	2010-07-20	Ct Ingenieria Genetica Biotech	Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP2012809B1 (en)	2006-03-10	2013-05-22	Ipsen Pharma	Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
CA2858907A1 (en) *	2006-09-08	2008-03-13	Bayer Schering Pharma Aktiengesellschaft	Compounds and methods for 18f labeled agents
JP5489333B2 (ja)	2006-09-22	2014-05-14	メルク・シャープ・アンド・ドーム・コーポレーション	脂肪酸合成阻害剤を用いた治療の方法
WO2008047544A1 (en)	2006-09-28	2008-04-24	Banyu Pharmaceutical Co., Ltd.	Diaryl ketimine derivative
MX2009003617A (es) *	2006-10-02	2009-04-22	Bayer Schering Pharma Ag	Derivados de silicio para obtencion de imagenes por tomografia de emision de positrones (pet).
US20080114055A1 (en) *	2006-11-10	2008-05-15	Zoltan Laboratories Llc	Thioxanthone Compounds to Reverse Weight Loss
CN101657436A (zh)	2007-02-09	2010-02-24	特兰齐姆制药公司	大环生长素释放肽受体调节剂及其使用方法
WO2008104203A2 (en) *	2007-03-01	2008-09-04	Bayer Schering Pharma Aktiengesellschaft	18f fluoro-benzoyl labelled biological active coumpounds as diagnositic imaging agents as well as benzotriazol-1-yloxy-benzoyl, 2,5-dioxo-pyrrolidin-1-yloxy) benzoyl and trimethylammonio-benzoyl precursers
WO2008110551A1 (en)	2007-03-12	2008-09-18	Zadec Aps	An anti-diabetic extract of rooibos
EP2002835A1 (en)	2007-06-04	2008-12-17	GenKyo Tex	Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
AU2008233662B2 (en)	2007-04-02	2012-08-23	Msd K.K.	Indoledione derivative
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en)	2007-06-04	2011-02-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2168602A4 (en) *	2007-06-12	2014-10-29	Inst Pharm & Toxicology Amms	LINEAR, PEGYLATED, SITE-SPECIFIC SALMON CALCITONIN DERIVATIVES
EP2264026A4 (en)	2008-03-06	2012-03-28	Msd Kk	ALKYLAMINOPYRIDINDERIVATE
EP2272841A1 (en)	2008-03-28	2011-01-12	Banyu Pharmaceutical Co., Ltd.	Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
AU2009256157B2 (en)	2008-06-04	2014-12-18	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2009154132A1 (ja)	2008-06-19	2011-12-01	Ｍｓｄ株式会社	スピロジアミン−ジアリールケトオキシム誘導体
JP2011528375A (ja)	2008-07-16	2011-11-17	シナジーファーマシューティカルズインコーポレイテッド	胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP2319841A1 (en)	2008-07-30	2011-05-11	Msd K.K.	(5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
EP2166009A1 (en)	2008-09-23	2010-03-24	Genkyo Tex Sa	Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2166010A1 (en)	2008-09-23	2010-03-24	Genkyo Tex Sa	Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2165707A1 (en)	2008-09-23	2010-03-24	Genkyo Tex Sa	Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
MX2011004258A (es)	2008-10-22	2011-06-01	Merck Sharp & Dohme	Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
JP5635991B2 (ja)	2008-10-30	2014-12-03	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	イソニコチンアミドオレキシン受容体アンタゴニスト
WO2010051206A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2305679A1 (en)	2009-09-28	2011-04-06	GenKyoTex SA	Pyrazoline dione derivatives as nadph oxidase inhibitors
EP2361912A1 (en)	2010-02-18	2011-08-31	GenKyoTex SA	Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2361911A1 (en) *	2010-02-18	2011-08-31	GenKyoTex SA	Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
WO2011106273A1 (en)	2010-02-25	2011-09-01	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011105611A1 (ja)	2010-02-26	2011-09-01	ラクオリア創薬株式会社	悪液質を治療するためのグレリン受容体作動物質
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
WO2012116145A1 (en)	2011-02-25	2012-08-30	Merck Sharp & Dohme Corp.	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
JP6113144B2 (ja) *	2011-04-21	2017-04-12	セラテクノロジーズ・インコーポレーテッド	成長ホルモン放出因子（ｇｒｆ）類似体およびその使用
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
TW201400506A (zh) *	2012-05-25	2014-01-01	Raqualia Pharma Inc	用於治療胃酸缺乏症之生長激素釋放肽受體促效劑
WO2014022528A1 (en)	2012-08-02	2014-02-06	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
EP3524260B1 (en)	2012-09-27	2023-09-13	Elanco Animal Health Incorporated	Pharmaceutical compositions for treatment of inappetence
EP2913063B1 (en)	2012-10-24	2019-09-11	Daiichi Sankyo Company, Limited	Therapeutic agent for use in treating amyotrophic lateral sclerosis
CA2898482A1 (en)	2013-02-22	2014-08-28	Linda L. Brockunier	Antidiabetic bicyclic compounds
AU2014235209B2 (en)	2013-03-15	2018-06-14	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists combined with other drugs
JP2016514671A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	グアニル酸シクラーゼのアゴニストおよびその使用
JP6337266B2 (ja) *	2013-05-28	2018-06-06	ラクオリア創薬株式会社	多形形態
AU2014274812B2 (en)	2013-06-05	2018-09-27	Bausch Health Ireland Limited	Ultra-pure agonists of guanylate cyclase C, method of making and using same
KR102051433B1 (ko) *	2013-08-27	2020-01-08	(주)네오팜	근육 분화 촉진 및 근육 강화용 조성물 및 외용제
US9119832B2 (en)	2014-02-05	2015-09-01	The Regents Of The University Of California	Methods of treating mild brain injury
CN106459147B (zh) *	2014-08-05	2021-08-06	拉夸里亚创药株式会社	作为生长激素释放肽受体激动剂的丝氨酸衍生物
US9708272B2 (en)	2014-08-29	2017-07-18	Tes Pharma S.R.L.	Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
WO2016067638A1 (en) *	2014-10-31	2016-05-06	Raqualia Pharma Inc.	Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists
WO2017075535A1 (en)	2015-10-28	2017-05-04	Oxeia Biopharmaceuticals, Inc.	Methods of treating neurodegenerative conditions
EP3526199B1 (en)	2016-10-14	2022-04-13	Tes Pharma S.r.l.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3479843A1 (en)	2017-11-01	2019-05-08	GenKyoTex Suisse SA	Use of nox inhibitors for treatment of cancer
MX2021005904A (es)	2018-11-20	2021-09-08	Tes Pharma S R L	Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa.
CN109320515A (zh) *	2018-11-22	2019-02-12	常州大学	一种Capromorelin手性中间体的不对称合成方法
EP3924058B1 (en)	2019-02-13	2026-01-07	Merck Sharp & Dohme LLC	5-alkyl pyrrolidine orexin receptor agonists
CN120265641A (zh) *	2023-04-21	2025-07-04	长春金赛药业有限责任公司	GHSR 1a激动剂、药物组合物及其制备方法和应用
CN119285632A (zh) *	2024-10-09	2025-01-10	威海中腾医药科技有限公司	一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE400557B (sv) *	1971-05-11	1978-04-03	Sandoz Ag	Forfarande for framstellning av nya kondenserade pyridaziner
DE2221808C2 (de) *	1972-05-04	1985-06-20	Sandoz-Patent-GmbH, 7850 Lörrach	Hydrazinopyridazin-Derivate, deren Säureadditionssalze, Verfahren zu deren Herstellung und Heilmittel
IL107836A (en) *	1992-12-11	1998-01-04	Merck & Co Inc	Spiro piperidines and homologues, their preparation and pharmaceutical preparations containing them
JP3670690B2 (ja) *	1993-10-04	2005-07-13	トーアエイヨー株式会社	３−ピリダジノン誘導体、その製造法およびそれを含有する循環器官用剤
CN1136278A (zh) *	1993-10-19	1996-11-20	麦克公司	双膦酸盐与生长激素促分泌素的组合
CZ134296A3 (en) *	1993-11-09	1996-12-11	Merck & Co Inc	Piperidine, pyrrolidine and hexahydro-1h-azepine derivatives, process of their preparation and pharmaceutical compositions containing thereof
US5935924A (en) *	1994-04-15	1999-08-10	Genentech, Inc.	Treatment of congestive heart failure
US5610134A (en) *	1994-04-15	1997-03-11	Genentech, Inc.	Treatment of congestive heart failure
US5767118A (en) *	1994-10-26	1998-06-16	Merck & Co., Inc.	4-Heterocyclic peperidines promote release of growth hormone
US5798337A (en) *	1994-11-16	1998-08-25	Genentech, Inc.	Low molecular weight peptidomimetic growth hormone secretagogues
PL186511B1 (pl) *	1995-01-27	2004-01-30	Novo Nordisk As	Nowe związki peptydowe, kompozycje farmaceutycznedo pobudzania uwalniania hormonu wzrostu i zastosowanie tych związków do wytwarzania leku do pobudzania uwalniania hormonu wzrostu
AU4534596A (en) *	1995-02-09	1996-08-27	Novo Nordisk A/S	Compounds with growth hormone releasing properties
WO1996024587A1 (en) *	1995-02-09	1996-08-15	Novo Nordisk A/S	Compounds with growth hormone releasing properties
EP0761220A1 (en) *	1995-08-21	1997-03-12	Eli Lilly And Company	2-Acylaminopropanamides as growth hormone secretagogues
ZA966891B (en) *	1995-08-21	1998-02-16	Lilly Co Eli	2-acylaminopropanamines as growth hormone secretagogues.
TW432073B (en) *	1995-12-28	2001-05-01	Pfizer	Pyrazolopyridine compounds
US6020358A (en) *	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels

1996
- 1996-11-13 TW TW085113857A patent/TW432073B/zh not_active IP Right Cessation
- 1996-11-14 AP APAP/P/1996/000881A patent/AP756A/en active
- 1996-12-04 IL IL138911A patent/IL138911A/en not_active IP Right Cessation
- 1996-12-04 BR BRPI9612465-2A patent/BR9612465B1/pt not_active IP Right Cessation
- 1996-12-04 IL IL13891096A patent/IL138910A0/xx unknown
- 1996-12-04 TR TR1998/01233T patent/TR199801233T2/xx unknown
- 1996-12-04 AU AU75850/96A patent/AU716934B2/en not_active Ceased
- 1996-12-04 PT PT96938434T patent/PT869968E/pt unknown
- 1996-12-04 CZ CZ19981995A patent/CZ293423B6/cs not_active IP Right Cessation
- 1996-12-04 SI SI9630755T patent/SI0869968T1/sl unknown
- 1996-12-04 CN CN96199388A patent/CN1113895C/zh not_active Expired - Lifetime
- 1996-12-04 UA UA98063368A patent/UA66754C2/xx unknown
- 1996-12-04 IL IL12444996A patent/IL124449A/en not_active IP Right Cessation
- 1996-12-04 DK DK96938434T patent/DK0869968T3/da active
- 1996-12-04 WO PCT/IB1996/001353 patent/WO1997024369A1/en not_active Ceased
- 1996-12-04 DE DE69637063T patent/DE69637063T2/de not_active Expired - Lifetime
- 1996-12-04 JP JP52412497A patent/JP3511382B2/ja not_active Expired - Lifetime
- 1996-12-04 KR KR10-1998-0704973A patent/KR100320167B1/ko not_active Expired - Lifetime
- 1996-12-04 EP EP96938434A patent/EP0869968B1/en not_active Expired - Lifetime
- 1996-12-04 ES ES96938434T patent/ES2285715T3/es not_active Expired - Lifetime
- 1996-12-04 AT AT96938434T patent/ATE361314T1/de not_active IP Right Cessation
- 1996-12-04 HU HU9901246A patent/HUP9901246A3/hu unknown
- 1996-12-04 NZ NZ322172A patent/NZ322172A/xx unknown
- 1996-12-04 PL PL96327634A patent/PL186916B1/pl not_active IP Right Cessation
- 1996-12-04 IL IL13890996A patent/IL138909A0/xx unknown
- 1996-12-04 SK SK874-98A patent/SK285678B6/sk not_active IP Right Cessation
- 1996-12-04 CA CA002241725A patent/CA2241725C/en not_active Expired - Lifetime
- 1996-12-06 HN HN1996000085A patent/HN1996000085A/es unknown
- 1996-12-09 AR ARP960105571A patent/AR004367A1/es active IP Right Grant
- 1996-12-19 GT GT199600100A patent/GT199600100A/es unknown
- 1996-12-20 CO CO96066996A patent/CO4480108A1/es unknown
- 1996-12-23 ZA ZA9610858A patent/ZA9610858B/xx unknown
- 1996-12-24 MA MA24438A patent/MA26415A1/fr unknown
- 1996-12-24 EG EG117796A patent/EG24195A/xx active
- 1996-12-24 TN TNTNSN96172A patent/TNSN96172A1/fr unknown
- 1996-12-26 MY MYPI96005499A patent/MY135727A/en unknown
- 1996-12-26 RS YUP-702/96A patent/RS49926B/sr unknown
- 1996-12-27 HR HR960618A patent/HRP960618B1/xx not_active IP Right Cessation
- 1996-12-27 PE PE1996000961A patent/PE30398A1/es not_active Application Discontinuation
1997
- 1997-01-27 SA SA97170581A patent/SA97170581B1/ar unknown
1998
- 1998-05-26 IS IS4758A patent/IS4758A/is unknown
- 1998-06-11 BG BG102533A patent/BG64055B1/bg unknown
- 1998-06-19 OA OA9800090A patent/OA10702A/en unknown
- 1998-06-24 MX MX9805157A patent/MX9805157A/es active IP Right Grant
- 1998-06-26 NO NO19982991A patent/NO325135B1/no not_active IP Right Cessation
1999
- 1999-03-01 US US09/259,691 patent/US6107306A/en not_active Expired - Lifetime
- 1999-03-01 US US09/259,776 patent/US6124264A/en not_active Expired - Lifetime
- 1999-03-01 US US09/258,956 patent/US6110932A/en not_active Expired - Lifetime
- 1999-05-27 AP APAP/P/1999/001555A patent/AP860A/en active
- 1999-12-22 US US09/470,668 patent/US6278000B1/en not_active Expired - Lifetime
2000
- 2000-06-13 US US09/593,582 patent/US6306875B1/en not_active Expired - Lifetime
- 2000-06-13 US US09/593,581 patent/US6313140B1/en not_active Expired - Lifetime
- 2000-12-11 US US09/734,274 patent/US6482825B2/en not_active Expired - Lifetime
- 2000-12-20 JP JP2000386997A patent/JP2001213800A/ja active Pending
2006
- 2006-03-03 AR ARP060100824A patent/AR052506A2/es active IP Right Grant

Also Published As

Publication number	Publication date
BR9612465A (pt)	1999-07-13
ES2285715T3 (es)	2007-11-16
ZA9610858B (en)	1998-06-23
NO325135B1 (no)	2008-02-04
US6110932A (en)	2000-08-29
US6313140B1 (en)	2001-11-06
JPH11501945A (ja)	1999-02-16
TR199801233T2 (xx)	1998-10-21
MX9805157A (es)	1998-10-31
US6124264A (en)	2000-09-26
HUP9901246A2 (hu)	1999-08-30
IL138911A (en)	2007-07-24
SI0869968T1 (sl)	2007-08-31
IL124449A0 (en)	1998-12-06
CN1113895C (zh)	2003-07-09
KR100320167B1 (ko)	2003-11-14
PE30398A1 (es)	1998-07-21
IS4758A (is)	1998-05-26
JP3511382B2 (ja)	2004-03-29
MY135727A (en)	2008-06-30
CA2241725C (en)	2002-06-18
IL138910A0 (en)	2001-11-25
OA10702A (en)	2001-05-07
AP9901555A0 (en)	1999-06-30
TNSN96172A1 (fr)	2005-03-15
EG24195A (en)	2008-10-14
HN1996000085A (es)	1997-06-18
CZ293423B6 (cs)	2004-04-14
CN1206422A (zh)	1999-01-27
WO1997024369A1 (en)	1997-07-10
NO982991D0 (no)	1998-06-26
DE69637063D1 (de)	2007-06-14
AR052506A2 (es)	2007-03-21
HRP960618A2 (en)	1998-04-30
BR9612465B1 (pt)	2010-08-10
JP2001213800A (ja)	2001-08-07
YU70296A (en)	1999-11-22
CO4480108A1 (es)	1997-07-09
US6107306A (en)	2000-08-22
AU7585096A (en)	1997-07-28
GT199600100A (es)	1998-06-12
IL138911A0 (en)	2001-11-25
AU716934B2 (en)	2000-03-09
CZ199598A3 (cs)	1999-05-12
ATE361314T1 (de)	2007-05-15
NO982991L (no)	1998-08-26
AP860A (en)	1999-08-06
NZ322172A (en)	2000-08-25
EP0869968B1 (en)	2007-05-02
UA66754C2 (en)	2004-06-15
PL327634A1 (en)	1998-12-21
HUP9901246A3 (en)	1999-11-29
US6278000B1 (en)	2001-08-21
BG64055B1 (bg)	2003-11-28
US6482825B2 (en)	2002-11-19
US6306875B1 (en)	2001-10-23
EP0869968A1 (en)	1998-10-14
PT869968E (pt)	2007-07-11
CA2241725A1 (en)	1997-07-10
KR19990076846A (ko)	1999-10-25
DE69637063T2 (de)	2008-02-07
IL124449A (en)	2004-06-01
MA26415A1 (fr)	2004-12-20
AR004367A1 (es)	1998-11-04
US20020049196A1 (en)	2002-04-25
DK0869968T3 (da)	2007-09-10
SA97170581B1 (ar)	2006-03-15
HRP960618B1 (en)	2007-12-31
PL186916B1 (pl)	2004-03-31
IL138909A0 (en)	2001-11-25
AP9600881A0 (en)	1997-01-31
SK87498A3 (en)	1999-08-06
BG102533A (en)	1999-09-30
SK285678B6 (sk)	2007-06-07
RS49926B (sr)	2008-09-29
AP756A (en)	1999-08-06

Publication	Publication Date	Title
TW432073B (en)	2001-05-01	Pyrazolopyridine compounds
ES2400983T3 (es)	2013-04-16	Ordenador portátil y procedimiento para precalentar el ordenador portátil antes de arrancar
BRPI0718221A2 (pt)	2013-11-12	Fonte luminosa, e, pacote de elemento emissor de luz
CN103462578B (zh)	2015-06-10	医用内窥镜、医用内窥镜冷光源系统及其温控系统
JP3158694U (ja)	2010-04-15	モジュール化されたｌｅｄ灯器具の冷却装置
JP2010272472A (ja)	2010-12-02	Ｌｅｄ照明装置
CN110446531B (zh)	2023-04-11	光疗设备
JP2012090950A (ja)	2012-05-17	光治療装置
CN201449586U (zh)	2010-05-05	计算机主机散热装置及其面板系统
TWM279352U (en)	2005-11-01	Photo power supply device capable of being controlled by programs
JP2002102164A (ja)	2002-04-09	電子内視鏡用プロセッサ及び内視鏡用光源装置
ES2249184B1 (es)	2007-07-16	Iluminador hibrido.
TWI566443B (zh)	2017-01-11	發光二極體散熱方法及發光裝置
TWM432073U (en)	2012-06-21	Heat dissipation fan with overheat alarming device
CN107995772A (zh)	2018-05-04	一种具有散热结构的背光源用fpc
CN115720398A (zh)	2023-02-28	多模态内窥镜冷光源led灯的过温保护控制电路及方法
TWM366026U (en)	2009-10-01	Lamp
TWM360979U (en)	2009-07-11	The LED streetlamp with temperature control.
CN219644145U (zh)	2023-09-05	一种便于散热的灯具电子镇流器
TW201122349A (en)	2011-07-01	Heat-dissipating module of a lamp
JP2011003516A (ja)	2011-01-06	Ｌｅｄ照明器具の構造。
CN116211579A (zh)	2023-06-06	一种止痒仪及其工作方法
TWI335791B (en)	2011-01-01	Dissipating heat device
TWI329179B (en)	2010-08-21	Illuminating device, power source module thereof and lamp incorporating the illuminating device
TW202538373A (zh)	2025-10-01	顯示系統及方法

Legal Events

Date	Code	Title	Description
2001-09-12	GD4A	Issue of patent certificate for granted invention patent
2010-02-11	MM4A	Annulment or lapse of patent due to non-payment of fees